GlobeNewswire Inc | Aug 7, 2020 08:30AM EDT

August 07, 2020

UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Merus N.V.(Nasdaq:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that Bill Lundberg, M.D., President and Chief Executive Officer, will present a company overview at the 2020Wedbush PacGrow Healthcare ConferenceonWednesday, August 12, 2020at10:20 a.m. ET.

A live webcast of the presentation will be available on the Investors page of the Company's website, http://www.merus.nl. An archived presentation will be available on the Merus website for a limited time.

About MerusMerusis a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics. Multiclonicsare manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus website,www.merus.nl and https://twitter.com/MerusNV.

Merus Investor and Media Inquiries:Jillian ConnellMerus N.V.Investor Relations and Corporate Communications617-955-4716j.connell@merus.nl